Sinovac Biotech Ltd. (Sinovac) is a holding company that conducts its business in China through its 71.56% majority owned subsidiary, Sinovac Beijing, its wholly owned subsidiaries, Tangshan Yian, Sinovac Biological and Sinovac Hong Kong, and its 30%-owned joint venture Sinovac Dalian. The Company is an integrated China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against infectious diseases. It has developed a portfolio of products, consisting of vaccines against the hepatitis A, hepatitis B and influenza viruses. The Company鈥檚 product pipeline also includes human vaccines for Japanese encephalitis, haemophilus influenzae type b (Hib), meningitis, rabies, chickenpox, mumps and rubella that has completed or are in pre-clinical development, and a vaccine for the severe acute respiratory syndrome (SARS), virus that has completed a Phase I clinical trial.